Overview

Study Evaluating GS-5245 in Participants With COVID-19 Who Have a High Risk of Developing Serious or Severe Illness

Status:
Recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to test if GS-5245 is safe and effective for the treatment of coronavirus disease 2019 (COVID-19) in participants who have a high risk of developing serious or severe illness. The study will also measure how much GS-5245 gets into the blood and how long it takes the body to get rid of it.
Phase:
Phase 3
Details
Lead Sponsor:
Gilead Sciences